Update: Medicate Is Not Planning To Pay For Expensive New Alzheimer’s Drug

Just a couple of days ago, I wrote a column about aducamumab (Aduhelm), a new Alzheimer’s treatment from Biogen. Medicare just announced that they agree with me.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive